Suppr超能文献

支架内再狭窄的治疗选择。

Therapeutic Options for In-Stent Restenosis.

机构信息

Division of Cardiovascular Diseases, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.

Division of Cardiovascular Diseases, Albert Einstein Health Center, Philadelphia, PA, USA.

出版信息

Curr Cardiol Rep. 2018 Feb 12;20(2):7. doi: 10.1007/s11886-018-0952-4.

Abstract

PURPOSE OF REVIEW

In-stent restenosis (ISR) is a complex disease process that became apparent shortly after the introduction of stents into clinical practice. This review seeks to define in-stent restenosis (ISR) as well as to summarize the major treatment options that have been developed and studied over the past two decades.

RECENT FINDINGS

Recent developments in drug-coated balloons and bioresorbable vascular scaffolds have added new potential treatments for ISR. Two recent network meta-analyses performed a head-to-head comparison of all the various treatment modalities in order to identify the best approach to management of ISR. Current data suggests that repeat stenting with second-generation drug-eluting stents is most likely to lead to the best angiographic and clinical outcomes. In situations where repeat stenting is not preferable, drug-coated balloon therapy seems to be a reasonably effective alternative.

摘要

目的综述

支架置入后不久,支架内再狭窄(ISR)即成为一种复杂的疾病过程。本综述旨在定义支架内再狭窄(ISR),并总结过去 20 年中已开发和研究的主要治疗选择。

最新发现

药物涂层球囊和生物可吸收血管支架的最新进展为 ISR 提供了新的潜在治疗方法。最近进行了两项网络荟萃分析,对头对头比较了所有各种治疗方式,以确定 ISR 管理的最佳方法。目前的数据表明,使用第二代药物洗脱支架进行再次支架置入最有可能获得最佳的血管造影和临床结果。在不适合再次支架置入的情况下,药物涂层球囊治疗似乎是一种合理有效的替代方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验